Molecular resistance: An early indicator for treatment change?

Clinical Lymphoma, Myeloma and Leukemia

Volumn 12, Issue 2, 2012, Pages 79-87

  Fava, Carmen ^a   Kantarjian, Hagop ^b   Cortes, Jorge ^b  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

BCR ABL inhibitor; Imatinib intolerance or resistance; Major molecular response; Monitoring response; Treatment failure

Indexed keywords

BCR ABL PROTEIN; DASATINIB; HOMOHARRINGTONINE; IMATINIB; NILOTINIB; PONATINIB; PROTEIN TYROSINE KINASE;

CANCER PROGNOSIS; CANCER REGRESSION; CANCER RELAPSE; CYTOGENETICS; DRUG DOSE ESCALATION; DRUG MEGADOSE; DRUG RESISTANCE; DRUG RESPONSE; DRUG TOLERABILITY; EVIDENCE BASED PRACTICE; HUMAN; LEUKEMIA; MOLECULAR BIOLOGY; PHASE 1 CLINICAL TRIAL (TOPIC); POINT MUTATION; PRACTICE GUIDELINE; PREDICTIVE VALUE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; TOXICITY; TRANSCRIPTION REGULATION; TREATMENT FAILURE; TREATMENT PLANNING;

ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PIPERAZINES; POINT MUTATION; PRACTICE GUIDELINES AS TOPIC; PROGNOSIS; PROTEIN KINASE INHIBITORS; PYRIMIDINES; TREATMENT OUTCOME;

EID: 84858963632     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.1016/j.clml.2011.12.004     Document Type: Review

References (90)

1. Sawyers CL. Chronic myeloid leukemia. N Engl J Med 1999; 340:1330-40. (Pubitemid 29196596)
2. Alvarez RH, Kantarjian H, Cortes JE. The biology of chronic myelogenous leukemia: implications for imatinib therapy. Semin Hematol 2007; 44(suppl 1):S4-14.
3. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Chronic myelogenous leukemia. Version 2.2012. Available at: http://www.nccn.org/professionals/physician-gls/f-guidelines.asp. Accessed: July 25, 2011.
4. Nowell PC, Hungerford DA. A minute chromosome in human chronic granulocytic leukemia. Science 1960; 132:1497.
5. Rowley JD. A new consistent abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 1973; 243:290-3.
6. Bartram CR, de Klein A, Hagemeijer A, et al. Translocation of c-abl oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia. Nature 1983; 306:277-80. (Pubitemid 14232360)
7. Groffen J, Stephenson JR, Heisterkamp N, et al. Philadelphia chromosome breakpoints are clustered within a limited region, bcr, on chromosome 22. Cell 1984; 36:93-9. (Pubitemid 14155374)
8. Lugo TG, Pendergast AM, Muller AJ, et al. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 1990; 247:1079-82.
9. Quintás-Cardama A, Cortes J. Molecular biology of bcr-abl1-positive chronic myeloid leukemia. Blood 2009; 113:1619-30.
10. Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996; 2:561-6.
11. O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003; 348:994-1004. (Pubitemid 36302244)
12. Druker BJ, Guilhot F, O'Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006; 355:2408-17. (Pubitemid 44903745)
13. de Lavallade H, Apperley JF, Khorashad JS, et al. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol 2008; 26:3358-63.
14. Kantarjian H, O'Brien S, Talpaz M, et al. Outcome of patients with Philadelphia chromosome-positive chronic myelogenous leukemia post-imatinib mesylate failure. Cancer 2007; 109:1556-60. (Pubitemid 46603580)
15. Fullmer A, Kantarjian H, Cortes J, et al. New developments in the treatment of chronic myeloid leukemia and Philadelphia-positive acute lymphoblastic leukemia. Leuk Lymphoma 2011; 52(suppl 1):81-91.
16. Rosti G, Palandri F, Castagnetti F, et al. Nilotinib for the frontline treatment of Ph+ chronic myeloid leukemia. Blood 2009; 114:4933-8.
17. Cortes JF, Jones D, O'Brien S, et al. Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase. J Clin Oncol 2010; 28:392-7.
18. Cortes JE, Jones D, O'Brien S, et al. Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia. J Clin Oncol 2010; 28:398-404.
19. Kantarjian H, Shah NP, Hochhaus A, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010; 362:2260-70.
20. Saglio G, Kim D-W, Issaragrisil S, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010; 362:2251-9.
21. Sprycel (dasatinib) tablets [prescribing information]: Princeton, NJ: Bristol-Myers Squibb; 2010.
22. Radich JP, Oehler V. Monitoring chronic myelogenous leukemia in the age of tyrosine kinase inhibitors. J Natl Compr Canc Netw 2007; 5:497-504. (Pubitemid 46815211)
23. Sawyers CL, Hochhaus A, Feldman E, et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 2002; 99:3530-9. (Pubitemid 34534519)
24. Talpaz M, Silver RT, Druker BJ, et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 2002; 99:1928-37. (Pubitemid 34525471)
25. Baccarani M, Cortes J, Pane F, et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 2009; 27:6041-51.
26. Hehlmann R, Hochhaus A, Baccarani M. Chronic myeloid leukemia. Lancet 2007; 370:342-50.
27. Marin D, Milojkovic D, Olavarria E, et al. European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor. Blood 2008; 112:4437-44.
28. Alvarado Y, Kantarjian H, O'Brien S, et al. Significance of suboptimal response to imatinib, as defined by the European LeukemiaNet, in the long-term outcome of patients with early chronic myeloid leukemia in chronic phase. Cancer 2009; 115:3709-18.
29. Hughes TP, Hochhaus A, Branford S, et al. Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon versus STI571 (IRIS). Blood 2010; 116:3758-65.
30. Press RD, Galderisi C, Yang R, et al. A half-log increase in BCR-ABL RNA predicts a higher risk of relapse in patients with chronic myeloid leukemia with an imatinib-induced complete cytogenetic response. Clin Cancer Res 2007; 13:6136-43. (Pubitemid 350075073)
31. Kantarjian HM, Shan J, Jones D, et al. Significance of increasing levels of minimal residual disease in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in complete cytogenetic response. J Clin Oncol 2009; 27:3659-63.
32. Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001; 293:876-80. (Pubitemid 32743979)
33. Bocchia M, Ippoliti M, Gozzetti A, et al. CD34+/Ph+ cells are still detectable in chronic myeloid leukemia patients with sustained and prolonged complete cytogenetic remission during treatment with imatinib mesylate. Leukemia 2008; 22:426-8. (Pubitemid 351250549)
34. Columbat M, Fort M-P, Chollet C, et al. Molecular remission in chronic myeloid leukemia patients with sustained complete cytogenetic remission after imatinib mesylate treatment. Haematologica 2006; 91:162-8.
35. Branford S, Seymour JF, Grigg A, et al. BCR-ABL messenger RNA levels continue to decline in patients with chronic phase chronic myeloid leukemia treated with imatinib for more than 5 years and approximately half of all first-line treated patients have stable undetectable BCR-ABL using strict sensitivity criteria. Clin Cancer Res 2007; 13:7080-5. (Pubitemid 350276891)
36. Branford S, Lawrence R, Grigg A, et al. Long term follow up of patients with CML in chronic phase treated with first-line imatinib suggests that earlier achievement of a major molecular response leads to greater stability of response [abstract]. Blood 2008; 112:2113.
37. Hess G, Meyer RG, Schuch B, et al. Sustained remissions and low rate of BCR-ABL resistance mutations with imatinib treatment chronic myelogenous leukemia in patients treated in late chronic phase. Am J Hematol 2008; 83:178-84. (Pubitemid 351303939)
38. Mahon F-X, Rea D, Guilhot F, et al. Discontinuation of imatinib therapy after achieving a molecular response in chronic myeloid leukemia patients [abstract]. Blood 2009; 114:859.
39. Hughes TP, Kaeda J, Branford S, et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 2003; 349:1423-32. (Pubitemid 37211057)
40. Cortes J, Talpaz M, O'Brien S, et al. Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate. Clin Cancer Res 2005; 11:3425-32. (Pubitemid 40627896)
41. Iacobucci I, Saglio G, Rosti G, et al. Achieving a major molecular response at the time of a complete cytogenic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients. Clin Cancer Res 2006; 12:3037-42. (Pubitemid 43837348)
42. Qin Y, Jiang B, Jiang Q, et al. Molecular responses of late chronic phase chronic myeloid leukemia patients after achieving complete cytogenetic responses with imatinib treatment: a 6-year follow-up. Ann Hematol 2009; 88:37-41.
43. Press RD, Love Z, Tronnes AA, et al. BCR-ABL levels at and after the time of a complete cytogenic response (CCR) predict the duration of CCR in imatinib mesylate-treated patients with CML. Blood 2006; 107:4250-6. (Pubitemid 43801348)
44. Kantarjian H, O'Brien S, Shan J, et al. Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia. Cancer 2008; 112:837-45. (Pubitemid 351240578)
45. Pavlovsky C, Giere I, Lombardi V, et al. Monitoring response to imatinib by quantitative real-time polymerase chain reaction (RQ-PCR) in chronic phase, chronic myeloid leukemia patients in complete cytogenetic remission [abstract]. J Clin Oncol 2008; 26(suppl): abstract 8013a. Available at: www.asco.org. Accessed: December 26, 2011.
46. Palandri F, Iacobucci I, Soverini S, et al. Treatment of Philadelphia-positive chronic myeloid leukemia with imatinib: importance of a stable molecular response. Clin Cancer Res 2009; 15:1059-63.
47. Merx K, Müller MC, Kreil S, et al. Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha. Leukemia 2002; 16:1579-83.
48. Wang L, Pearson K, Ferguson JE, et al. The early molecular response to imatinib predicts cytogenetic and clinical outcome in chronic myeloid leukaemia. Br J Haematol 2003; 120:990-9. (Pubitemid 36411558)
49. Quintás-Cardama A, Kantarjian H, Jones D, et al. Delayed achievement of cytogenetic and molecular response is associated with increased risk of progressions among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose therapy. Blood 2009; 113:6315-21.
50. Branford S, Rudzki Z, Harper A, et al. Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Leukemia 2003; 17:2401-9. (Pubitemid 38072578)
51. Kantarjian HM, Talpaz M, Giles F, et al. New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance. Ann Intern Med 2006; 145:913-23. (Pubitemid 351639967)
52. Branford S, Rudzki Z, Parkinson I, et al. Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations. Blood 2004; 104:2926-32. (Pubitemid 39434981)
53. Hochhaus A, Kantarjian HM, Baccarani M, et al. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood 2007; 109:2303-9. (Pubitemid 46425867)
54. Kantarjian HM, Giles F, Gattermann N, et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood 2007; 110:3540-6. (Pubitemid 350159618)
55. Shah NP, Kantarjian HM, Kim DW, et al. Intermittent target inhibition with dasatinib (100 mg once daily) preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. J Clin Oncol 2008; 226:3204-12.
56. Khorashad JS, de Lavallade H, Apperley JF, et al. Finding of kinase domain mutations in patients with chronic phase chronic myeloid leukemia responding to imatinib may identify those at high risk of disease progression. J Clin Oncol 2008; 29:4806-13.
57. Branford S, Goh H, Izzo B, et al. A review of mutation analysis in the TOPS trial of standard dose versus high dose IM in CML suggests that refinements to the ELN recommendations for mutation screening may be appropriate [abstract]. Blood 2010; 116:889.
58. Apperley JF. Part I: mechanisms of resistance to imatinib in chronic myeloid leukemia. Lancet Oncol 2007; 8:1018-29. (Pubitemid 47629897)
59. Deininger M, Buchdunger E, Druker BJ. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 2005; 105:2640-53. (Pubitemid 40446252)
60. Jabbour E, Kantarjian H, Jones D, et al. Characteristics and outcome of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy. Blood 2008; 112:53-5.
61. Nicolini FE, Hayette S, Corm S, et al. Clinical outcome of 27 imatinib mesylate-resistant chronic myelogenous leukemia patients harboring a T315I BCR-ABL mutation. Haematologica 2007; 92:1238-41. (Pubitemid 350144183)
62. Branford S, Rudzki Z, Walsh S, et al. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood 2003; 102:276-83. (Pubitemid 36759665)
63. O'Hare T, Walters DK, Stoffregen EP, et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 2005; 65:4500-5. (Pubitemid 40740783)
64. Soverini S, Martinelli G, Rosti G, et al. ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia. J Clin Oncol 2005; 23:4100-9. (Pubitemid 46211315)
65. Jabbour E, Kantarjian H, Jones D, et al. Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate. Leukemia 2006; 20:1767-73. (Pubitemid 44574988)
66. Hughes T, Saglio G, Branford S, et al. Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase. J Clin Oncol 2009; 27:4204-10.
67. Branford S, Shou Y, Lawrence R, et al. The P-loop mutations Y235H and E255K/V may develop more frequently than T315I during nilotinib therapy after imatinib failure and are associated with progression in patients with Ph-positive leukemia [abstract]. Haematologica 2007; 92(suppl 1):337-8.
68. Cortes J, Jabbour E, Kantarjian H, et al. Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors. Blood 2007; 110:4005-11. (Pubitemid 350248456)
69. Cortes J, Rousselot P, Kim D-W, et al. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood 2007; 109:3207-13. (Pubitemid 46572505)
70. Guilhot F, Apperley J, Kim DW, et al. Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase. Blood 2007; 109:4143-50. (Pubitemid 46743375)
71. Ottmann O, Dombret H, Martinelli G, et al. Dasatinib induces rapid hematologic and cytogenetic responses in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia with resistance to intolerance to imatinib: interim results of a phase II study. Blood 2007; 110:2309-15. (Pubitemid 47523149)
72. Soverini S, Colarossi S, Gnani A, et al. Resistance to dasatinib in Philadelphiapositive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain. Haematologica 2007; 92:401-4. (Pubitemid 350143551)
73. Müller MC, Cortes JC, Kim D-W, et al. Dasatinib treatment of chronic phase chronic myeloid leukemia: analysis of responses according to pre-existing BCR-ABL mutations. Blood 2009; 114:4944-53.
74. Picard S, Titier K, Etienne G, et al. Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood 2007; 109:3496-9. (Pubitemid 46572540)
75. Forrest DL, Trainor S, Brinkman RR, et al. Cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia are correlated with Sokal risk scores and duration of therapy but not trough imatinib plasma levels. Leukemia Res 2009; 33:271-5.
76. Rea D, Etienne G, Corm S, et al. Imatinib dose escalation for chronic phase-chronic myelogenous leukemia patients in primary suboptimal response to imatinib 400 mg daily standard therapy. Leukemia 2009; 23:1193-6.
77. Kim DY, Kim HJ, Jeong JS, et al. Efficacy of imatinib mesylate dose-escalation in CML patients showing suboptimal response to standard dose [abstract]. Blood 2007; 110:2967.
78. Jabbour E, Kantarjian H, Atallah E, et al. Impact of imatinib mesylate dose escalation on resistance and sub-optimal responses to standard-dose therapy in patients (pts) with chronic myeloid leukemia (CML) [abstract]. Blood 2007; 110:1035.
79. Batra U, Dasappa L, Lakshmiah KC, et al. Dose escalation of imatinib in CML patients with sub-optimal response to conventional dosage: is it worth it? [abstract]. J Clin Oncol 2008; 26(suppl): abstract 18026. Available at: www.asco.org. Accessed: December 26, 2011.
80. Sun SX, Fincher CL, Wang J, et al. Real-world adherence rates of chronic myeloid leukemia patients to higher doses of imatinib. J Manag Care Pharm 2007; 13:705-6.
81. Nicolini FE, Kim D-W, Ceglarek B, et al. Impact of prior therapy and suboptimal response to imatinib on the efficacy and safety of nilotinib among 1,422 patients with imatinib-resistant or -intolerant chronic myeloid leukemia (CML) in chronic phase (CP): sub-analyses of the ENACT (Expanding Nilotinib Access in Clinical Trials) study [abstract]. Blood 2009; 114:2201.
82. Yang AS, Jillella A, Miller CB, et al. Nilotinib-associated molecular responses achieved in chronic myeloid leukemia in chronic phase (CML-CP) patients with a suboptimal molecular response to imatinib [abstract]. Blood 2009; 114:2206.
83. Soverini S, Colarossi S, Gnani A, et al. Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia. Clin Cancer Res 2006; 12:7374-9. (Pubitemid 46095411)
84. Willis SG, Lange T, Demehri S, et al. High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy. Blood 2005; 106:2128-37. (Pubitemid 41291730)
85. White DL, Dang P, Engler J, et al. Functional activity of the OCT-1 protein is predictive of long-term outcome in patients with chronic-phase chronic myeloid leukemia treated with imatinib. J Clin Oncol 2010; 28:2761-7.
86. White DL, Saunders VA, Dang P, et al. OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib. Blood 2006; 108:697-704. (Pubitemid 44061372)
87. White DL, Saunders VA, Dang P, et al. Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity. Blood 2007; 110:4064-72. (Pubitemid 350248463)
88. Hiwase DK, Saunders V, Hewett D, et al. Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implications. Clin Cancer Res 2008; 14:3881-8.
89. Giannoudis A, Davies A, Lucas CM, et al. Effective dasatinib uptake may occur without human organic cation transporter 1 (hOCT1): implications for the treatment of imatinib-resistant chronic myeloid leukemia. Blood 2008; 112:3348-54.
90. Hochhaus A, Druker BJ, Larson RA, et al. IRIS 6-year follow-up: sustained survival and declining annual rate of transformation in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib [abstract]. Blood 2007; 110:25a.